Biogen
FDA Narrows Aduhelm Label
The FDA recently updated the label for Biogen's controversial Alzheimer’s drug.
JULY 12, 2021
FDA Approves Truxima, First Biosimilar to Rituxan
Truxima can be used to treat three types of adults with non-Hodgkin lymphoma.
NOVEMBER 29, 2018
FDA Approves First Drug for Spinal Muscular Atrophy
Spinraza improved motor function in SMA patients; a greater percentage of infantile-onset patients survived.
DECEMBER 27, 2016
Load more